-
Mashup Score: 0FDA Approves Momelotinib for Patients With Intermediate or High-Risk Myelofibrosis, Including Primary or Secondary MF, With Anemia - 7 month(s) ago
On September 15, 2023, the FDA granted approval for momelotinib for the treatment of intermediate or high-risk myelofibrosis, including primary and secondary myelofibrosis, for patients with anemia.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Momelotinib Impacts Treatment Methods for Anemia in Myelofibrosis - 7 month(s) ago
Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Following the FDA approval of #momelotinib on September 15, @AaronGerds, MD, MS, provides results of the phase 3 MOMENTUM study. #mpnsm | @ClevelandClinic https://t.co/VtHmyBT010
-
-
Mashup Score: 8Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia | GSK - 7 month(s) ago
Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
Source: www.gsk.comCategories: Latest Headlines, Partners & KOLsTweet-
Approval of Momelotinib is an important step forward in historically tough-to-treat patient population #myelofibrosis patients with anemia #mpnsm https://t.co/d6ZCWDRjwg
-
👉👉👉Breaking news 🗞️ ➡️ #Momelotinib #JAK #ACVR1 approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia | #MPNSM @mpdrc @AaronGerds @PedsHemeDoc @RaajitRampal https://t.co/oDLkUXfmQo
-
-
Mashup Score: 0Momelotinib Shows Durability and Safety in Myelofibrosis at 48 Weeks - 11 month(s) ago
Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial of momelotinib, a JAK1/JAK2 inhibitor that is being investigated specifically for the treatment of anemic patients with myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial of #momelotinib for the treatment of anemia in patients with #myelofibrosis. #mpnsm | @ClevelandClinic https://t.co/QQOFkOgq4O
-
-
Mashup Score: 2MOMENTUM: Momelotinib Improved Myelofibrosis Symptoms, Associated Anemia Measures | ASH Clinical News | American Society of Hematology - 12 month(s) ago
The first-in-class ACVR1, JAK1, and JAK2 inhibitor, momelotinib significantly improved myelofibrosis-associated symptoms, anemia measures, and splenomegaly in patients with anemia and myelofibrosis, according to results of the phase III MOMENTUM trial published in the Lancet. Srdan Verstovsek, MD, of the University of Texas MD Anderson Cancer Center, and colleagues conducted the international,…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
In the phase III MOMENTUM trial, #momelotinib, a first-in-class ACVR1, JAK1, and JAK2 inhibitor, was found to significantly improve myelofibrosis-associated symptoms, #anemia measures, and #splenomegaly in patients with anemia and #myelofibrosis https://t.co/XUZg5KitXY
-
-
Mashup Score: 0Potential Role of Momelotinib in Myelofibrosis - 1 year(s) ago
Aaron Gerds, MD, MS, discusses the MOMENTUM study and the potential role of momelotinib in the myelofibrosis treatment landscape.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Listen to expert @AaronGerds, MD, MS, discuss the MOMENTUM study and the potential role of #momelotinib in the #myelofibrosis treatment landscape. #mpnsm | @ClevelandClinic https://t.co/Pp2GYRxYLb
-
-
Mashup Score: 0
Srdan Verstovsek, MD, PhD, discusses the importance of the findings of the MOMENTUM trial, which assessed the use of momelotinib in managing anemia for patients with myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Srdan Verstovsek, MD, PhD, discusses the importance of the findings of the MOMENTUM trial, which assessed the use of #momelotinib in managing anemia for patients with #myelofibrosis. #mpnsm | @MDAndersonNews https://t.co/M4TYKOGBsJ
-
-
Mashup Score: 0JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis - 1 year(s) ago
Patients see reductions in spleen size, require fewer transfusions with momelotinib over danazol
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#Myelofibrosis treatment w/ the JAK inhibitor #momelotinib resulted in clinically significant improvements in symptoms & spleen response compared w/ #danazol for symptomatic, JAK inhibitor-exposed patients w/ anemia & intermediate- or high-risk disease. https://t.co/lzWOYf4ji9
-
-
Mashup Score: 0VIDEO: Momelotinib benefits maintained at 24 weeks in patients with anemic myelofibrosis - 1 year(s) ago
NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.In the study of momelotinib vs. danazol in symptomatic patients with anemic myelofibrosis previously treated with a JAK inhibitor, patient responses showed
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Momelotinib benefits maintained at 24 weeks in patients with anemic myelofibrosis. https://t.co/aHRHfOinEz @ClevelandClinic #ASH22 @ASH_hematology #HemOnc #OncAlert #MedEd #Momelotinib
-
-
Mashup Score: 0
In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed phase 3 MOMENTUM study and how it has impacted the clinical trial development of momelotinib for the treatment of patients with myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed phase 3 MOMENTUM study and how it has impacted the clinical trial development of #momelotinib for the treatment of patients with #myelofibrosis. #mpn @ClevelandClinic @AaronGerds https://t.co/XbirhdRXFs
-
Exciting news! On 9/15, the #FDA approved #momelotinib for intermediate/high-risk #myelofibrosis. This is the first and only approved medicine for both newly diagnosed and previously treated patients with #MF and anemia. Learn more: https://t.co/4D8tuxvnUT @FDAOncology @US_FDA https://t.co/Hlv42RS45a